DRAMP 2.0, an updated data repository of antimicrobial peptides
By X. Kang, Fanyi Dong, Cheng Shi, Shicai Liu, Jian Sun, Jiaxing Chen, Haiqi Li, Hanmei Xu, Xingzhen Lao, Heng Zheng. Scientific Data, 2019
304 citations recorded by the source corpus.
Data Repository of Antimicrobial Peptides (DRAMP, http://dramp.cpu-bioinfor.org/) is an open-access comprehensive database containing general, patent and clinical antimicrobial peptides (AMPs). Currently DRAMP has been updated to version 2.0, it contains a total of 19,899 entries (newly added 2,550 entries), including 5,084 general entries, 14,739 patent entries, and 76 clinical entries. The update covers new entries, structures, annotations, classifications and downloads. Compared with APD and CAMP, DRAMP contains 14,040 (70.56% in DRAMP) non-overlapping sequences. In order to facilitate users to trace original references, PubMed_ID of references have been contained in activity information. The data of DRAMP can be downloaded by dataset and activity, and the website source code is also available on dedicatedly designed download webpage. Although thousands of AMPs have been reported, only a few parts have entered clinical stage. In the paper, we described several AMPs in clinical trials, including their properties, indications and clinicaltrials.gov identifiers. Finally, we provide the applications of DRAMP in the development of AMPs.
Subfields: Microbiology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/87198cbcf8646f944e68226163a26c5d07e001a6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- A. Gabrielian
- D. Hurt
- Evgenia Alimbarashvili
- Anthony A Amstrong
- Mindia Chubinidze
- Michael Tartakovsky
- M. Pirtskhalava
- B. Vishnepolsky
Citations in the corpus
- DBAASP v3: database of antimicrobial/cytotoxic activity and structure of peptides as a resource for development of new therapeutics (2020, background): “Another database, DRAMP (2), which derives its data largely from patents, has information on clinical trials of 76 AMPs.”